Sample possesses significant inhibitory activity against Streptococcus pneumoniae and moderate activity against Neisseria gonorrhoeae, Streptococcus agalactiae, and Cryptococcus neoformans.

Specialized in combating Streptococcus pneumoniae and Neisseria gonorrhoeae, this fraction presents an exciting opportunity for developing targeted and specific treatments. Additionally, its moderate activity against Streptococcus agalactiae and Cryptococcus neoformans highlights its versatility and potential in treating complex and resistant infections. These results further support the importance of research in the quest for effective compounds against bacterial and fungal infections, underscoring the value of HB4Y1E as a promising candidate in this field of study.

Know more about the pathogens